Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, APRIL 22, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) A CLINICAL STAGE DEVELOPMENT COMPANY BASED IN SAN DIEGO AND FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT DR. HENDRICK SCHOLL, CHIEF MEDICAL OFFICER, WILL PRESENT AT THE DEUTSCHE BANK AMERICAN DEPOSITARY RECEIPT (ADR) VIRTUAL INVESTOR CONFERENCE (DBVIC) ON APRIL 28TH, 2026. THIS VIRTUAL INVESTOR CONFERENCE IS AIMED EXCLUSIVELY AT INTRODUCING GLOBAL COMPANIES WITH ADR PROGRAMS TO INVESTORS. DETAILS OF THE PRESENTATION ARE AS FOLLOWS:

BELITE BIO TO PRESENT AT THE DEUTSCHE BANK AMERICAN DEPOSITARY RECEIPT VIRTUAL INVESTOR CONFERENCE ON APRIL 28TH

SAN DIEGO, MARCH 31, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT ITS ANNUAL REPORT ON FORM 20-F, CONTAINING AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2025, AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 31, 2026, IS AVAILABLE THROUGH ITS WEBSITE (HTTPS:// WWW.BELITEBIO.COM ). SHAREHOLDERS MAY RECEIVE A HARD COPY OF THE ANNUAL REPORT FREE OF CHARGE UPON REQUEST. THIS PRESS RELEASE IS BEING ISSUED PURSUANT TO NASDAQ LISTING RULE 5250(D)(1)(C).

BELITE BIO ANNOUNCES AVAILABILITY OF ANNUAL REPORT ON FORM 20-F THROUGH COMPANY WEBSITE

SAN DIEGO, MARCH 02, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ITS PRELIMINARY, UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

BELITE BIO REPORTS PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 2,272,727 AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING ONE OF ITS ORDINARY SHARES, AT A PUBLIC OFFERING PRICE OF $154.00 PER ADS. THE COMPANY HAS ALSO GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 340,909 ADDITIONAL ADSS FROM THE COMPANY AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS OF THE OFFERING TO THE COMPANY ARE EXPECTED TO BE APPROXIMATELY $350.0 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY BELITE BIO. ALL OF THE SECURITIES IN THE OFFERING ARE TO BE SOLD BY BELITE BIO. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT DECEMBER 3, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

BELITE BIO ANNOUNCES PRICING OF $350.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC(NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING ONE OF ITS ORDINARY SHARES. ALL OF THE SECURITIES IN THE OFFERING ARE TO BE SOLD BY BELITE BIO. IN ADDITION, BELITE BIO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL ADSS AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSION. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

BELITE BIO ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY) TODAY ANNOUNCED TOPLINE RESULTS FROM THE GLOBAL PHASE 3 DRAGON TRIAL OF TINLAREBANT, MARKING THE FIRST SUCCESSFUL PIVOTAL TRIAL IN PATIENTS WITH STARGARDT DISEASE TYPE 1 (STGD1). STGD1 IS AN EYE DISEASE THAT LEADS TO PROGRESSIVE VISION LOSS, USUALLY BEGINNING IN CHILDHOOD OR YOUNG ADULTHOOD, AND CURRENTLY HAS NO APPROVED TREATMENT WORLDWIDE.

NEW HOPE FOR PEOPLE LIVING WITH A DISEASE ONCE DEEMED UNTREATABLE: BELITE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PIVOTAL GLOBAL, PHASE 3 DRAGON TRIAL OF TINLAREBANT IN ADOLESCENTS WITH STARGARDT DISEASE

COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ONLINE AT VIRTUALINVESTORCONFERENCES.COM COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ONLINE AT VIRTUALINVESTORCONFERENCES.COM

BELITE BIO TO PRESENT AT THE DBVIC - DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE NOVEMBER 4TH

SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- BELITE BIO INC(NASDAQ: BLTE) (BELITE OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAYANNOUNCED THAT THE EXECUTIVE MANAGEMENT TEAM WILL PRESENT AT THE DEUTSCHE BANK AMERICAN DEPOSITARY RECEIPT (ADR) VIRTUAL INVESTOR CONFERENCE HOSTED BY VIRTUALINVESTORCONFERENCES.COM, ON NOVEMBER 4, 2025. DETAILS OF THE PRESENTATION ARE AS FOLLOWS:

BELITE BIO TO PARTICIPATE IN THE DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE

SAN DIEGO, OCT. 15, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE CENTER FOR DRUG EVALUATION OF CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS AGREED TO ACCEPT THE NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE BASED ON THE INTERIM ANALYSIS RESULTS FROM THE PHASE 3 DRAGON TRIAL.

BELITE BIO ANNOUNCES CHINA NMPA AGREES TO NEW DRUG APPLICATION WITH PRIORITY REVIEW BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT

SAN DIEGO, AUG. 11, 2025 (GLOBE NEWSWIRE) -- BELITE BIO,INC(NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025, AND PROVIDED A GENERAL BUSINESS UPDATE.

Belite Bio, Inc

BLTE

Price

Financial Reports

No items found.

Press Releases

Belite Bio, Inc

BLTE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BLTE